Cargando…
EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant dise...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896/ https://www.ncbi.nlm.nih.gov/pubmed/23056941 http://dx.doi.org/10.1155/2012/901320 |
_version_ | 1782245606631145472 |
---|---|
author | Kono, Scott A. Haigentz, Missak Yom, Sue S. Saba, Nabil |
author_facet | Kono, Scott A. Haigentz, Missak Yom, Sue S. Saba, Nabil |
author_sort | Kono, Scott A. |
collection | PubMed |
description | Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant disease is present. Many patients with localized disease are treated with chemoradiotherapy, either in the definitive or adjuvant setting, and those with metastatic disease are treated with palliative chemotherapy. The chemotherapy used in SCCHN can be toxic, whether given with radiation or alone. The epidermal growth factor receptor (EGFR) is highly expressed in SCCHN and serves as a logical therapeutic target. EGFR-directed monoclonal antibodies (MoAbs) have higher activity in SCCHN than small molecule tyrosine kinase inhibitors. Cetuximab, a widely studied EGFR MoAb, is FDA approved in the metastatic setting, as well as with radiation for locally advanced disease. Despite improvements in survival when cetuximab is incorporated with chemotherapy for metastatic disease, the prognosis of patients remains poor. Novel EGFR MoAbs are being developed with the goal of improving efficacy and tolerability. This paper will summarize the use of EGFR-directed MoAbs in treating SCCHN with a focus on novel agents being tested. |
format | Online Article Text |
id | pubmed-3465896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34658962012-10-10 EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab Kono, Scott A. Haigentz, Missak Yom, Sue S. Saba, Nabil Chemother Res Pract Review Article Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant disease is present. Many patients with localized disease are treated with chemoradiotherapy, either in the definitive or adjuvant setting, and those with metastatic disease are treated with palliative chemotherapy. The chemotherapy used in SCCHN can be toxic, whether given with radiation or alone. The epidermal growth factor receptor (EGFR) is highly expressed in SCCHN and serves as a logical therapeutic target. EGFR-directed monoclonal antibodies (MoAbs) have higher activity in SCCHN than small molecule tyrosine kinase inhibitors. Cetuximab, a widely studied EGFR MoAb, is FDA approved in the metastatic setting, as well as with radiation for locally advanced disease. Despite improvements in survival when cetuximab is incorporated with chemotherapy for metastatic disease, the prognosis of patients remains poor. Novel EGFR MoAbs are being developed with the goal of improving efficacy and tolerability. This paper will summarize the use of EGFR-directed MoAbs in treating SCCHN with a focus on novel agents being tested. Hindawi Publishing Corporation 2012 2012-09-27 /pmc/articles/PMC3465896/ /pubmed/23056941 http://dx.doi.org/10.1155/2012/901320 Text en Copyright © 2012 Scott A. Kono et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kono, Scott A. Haigentz, Missak Yom, Sue S. Saba, Nabil EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab |
title | EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab |
title_full | EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab |
title_fullStr | EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab |
title_full_unstemmed | EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab |
title_short | EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab |
title_sort | egfr monoclonal antibodies in the treatment of squamous cell carcinoma of the head and neck: a view beyond cetuximab |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896/ https://www.ncbi.nlm.nih.gov/pubmed/23056941 http://dx.doi.org/10.1155/2012/901320 |
work_keys_str_mv | AT konoscotta egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab AT haigentzmissak egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab AT yomsues egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab AT sabanabil egfrmonoclonalantibodiesinthetreatmentofsquamouscellcarcinomaoftheheadandneckaviewbeyondcetuximab |